The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.9M data for 1.2M Compounds and 9.3K Targets. Of those, 1,352K data for 627K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

34 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.EBI
Kezar Life Sciences
Structure-based design of฿1i or฿5i specific inhibitors of human immunoproteasomes.EBI
Leiden Institute of Chemistry and Netherlands Proteomics Centre
Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome.EBI
Weill Cornell Medical College
Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.EBI
Hokkaido University
Molecular mechanisms of acquired proteasome inhibitor resistance.EBI
University of California San Diego
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).EBI
Proteolix
Identification of N, C-capped di- and tripeptides as selective immunoproteasome inhibitors.EBI
Chinese Academy of Medical Sciences and Peking Union Medical College
Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (?5i).EBI
Merck
Design, Synthesis, and Optimization of Macrocyclic Peptides as Species-Selective Antimalaria Proteasome Inhibitors.EBI
Weill Cornell Medicine
Cell-based screening of extracts of natural sources to search for inhibitors of the ubiquitin-proteasome system and identification of proteasome inhibitors from the fungus Remotididymella sp.EBI
Kumamoto University
Macrocyclic Peptides that Selectively Inhibit the EBI
Weill Cornell Medicine
Development of peptide epoxyketones as selective immunoproteasome inhibitors.EBI
Zhejiang University
Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease.EBI
University of Kentucky
Discovery of selective fragment-sized immunoproteasome inhibitors.EBI
Hungarian Academy of Sciences
A new class of ?-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.EBI
Tsinghua University
Structure-Activity Relationships of Noncovalent Immunoproteasome ?5i-Selective Dipeptides.EBI
Weill Cornell Medicine
Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.EBI
The University of Melbourne
Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.EBI
Hangzhou Xixi Hospital
LMP2 Inhibitors as a Potential Treatment for Alzheimer's Disease.EBI
University of Kentucky
Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.EBI
Hangzhou Institute of Innovative Medicine
Selective Phenylimidazole-Based Inhibitors of the EBI
Weill Cornell Medicine
Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors.EBI
Zhejiang University
Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide).EBI
Kezar Life Sciences
Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.EBI
Hangzhou Xixi Hospital
Structure-Based Design of Inhibitors Selective for Human Proteasome ?2c or ?2i Subunits.EBI
Leiden Institute of Chemistry and Netherlands Proteomics Centre
Improvement of Asparagine Ethylenediamines as Anti-malarial EBI
Weill Cornell Medicine
The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders.EBI
Purdue University
Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.EBI
Zhejiang University
Tetradehydrohalicyclamine B, a new proteasome inhibitor from the marine sponge Acanthostrongylophora ingens.EBI
Kumamoto University
Design, synthesis, and evaluation of cystargolide-based ?-lactones as potent proteasome inhibitors.EBI
New Mexico Institute of Mining and Technology
Structure-based design of human immuno- and constitutive proteasomes inhibitors.EBI
Universit£
Potent and Highly Selective Inhibitors of the Proteasome Trypsin-like Site by Incorporation of Basic Side Chain Containing Amino Acid Derived Sulfonyl Fluorides.EBI
University of Glasgow
Characterization of muscarinic M4 binding sites in rabbit lung, chicken heart, and NG108-15 cells.BDB
Glaxo Group Research